Loading…
Bicycle Therapeutics plc is projected to rise to $3.91 by 2027, a +1% move from its current price of $3.86. BCYC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.78 | $3.86 | $3.95 | 0.00% |
| Aug 4 | $3.74 | $3.86 | $3.98 | -0.01% |
| Aug 5 | $3.71 | $3.86 | $4.01 | -0.01% |
| Aug 6 | $3.69 | $3.86 | $4.03 | -0.01% |
| Aug 7 | $3.67 | $3.86 | $4.05 | -0.02% |
| Aug 8 | $3.66 | $3.86 | $4.07 | -0.02% |
| Aug 9 | $3.64 | $3.86 | $4.09 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.64 | $3.86 | $4.09 | -0.02% |
| Week 2 | $3.55 | $3.86 | $4.19 | -0.04% |
| Week 3 | $3.49 | $3.86 | $4.27 | -0.07% |
| Week 4 | $3.43 | $3.86 | $4.33 | -0.09% |
| Week 5 | $3.38 | $3.86 | $4.39 | -0.11% |
| Week 6 | $3.34 | $3.85 | $4.45 | -0.13% |
| Week 7 | $3.30 | $3.85 | $4.50 | -0.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Its products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB.
Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC trades at $3.87 per share and has a market cap of $270.17M. It is ranked 3380.
The current price and market position provide a baseline for assessing the price trajectory, with a long-run forecast showing gradual to strong upside beyond the near term.
The near-term forecast is modest, with 2026 averaging $3.87 and rising through 2029 to $4.19 on average, before a clearer bullish shift begins in 2030 with an average of $4.98 and a max of $6.79.
Looking further out, the multi-year outlook turns bullish from 2030 onward, with 2031–2035 printed as bullish and higher price targets appearing in 2040 and 2050. The 2040 average is $8.37 and the 2050 average is $16.73, with corresponding max prices of $12.76 and $27.36 respectively, and ROIs of 116.2% by 2040 and 332.4% by 2050.
A major floor 9.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 14.2% above — a clean break opens room to run.
A major ceiling 38.1% above — clearing it would confirm fresh momentum.
Key BCYC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCYC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.92 | Sell | $3.94 | Sell |
| MA 10 | $4.02 | Sell | $4.00 | Sell |
| MA 20 | $4.15 | Sell | $4.08 | Sell |
| MA 50 | $4.20 | Sell | $4.25 | Sell |
| MA 100 | $4.51 | Sell | $4.64 | Sell |
| MA 200 | $5.61 | Sell | $5.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.50 | Neutral |
| Stoch RSI (14) | 30.94 | Neutral |
| CCI (20) | -137.40 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -8.53 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 31.06 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 3.87 | Sell |
| ADX (14) | 15.77 | Neutral |
| ATR (14) | 0.09 | Info |
Sentiment is BEARISH in the near term.
RSI14 is 50, suggesting neutral momentum near the cusp of overbought/oversold. The 50-day simple moving average is $4.28 and the 200-day simple moving average is $5.74, indicating the price is currently trading below longer-term trend levels.
Support sits at $3.96 and resistance at $4.41. The 30-day range runs from $3.46 to $4.32, and annualized volatility is 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.86 | $3.86 | $4.69 | 0% | Neutral | |
| $3.17 | $3.91 | $5.06 | +1% | Neutral | |
| $3.31 | $4.17 | $5.56 | +8% | Neutral | |
| $3.23 | $4.14 | $5.66 | +7% | Neutral | |
| $3.75 | $4.90 | $6.84 | +27% | Bullish | |
| $4.24 | $5.62 | $7.99 | +46% | Bullish | |
| $4.09 | $5.49 | $7.93 | +42% | Bullish | |
| $4.22 | $5.74 | $8.41 | +49% | Bullish | |
| $4.22 | $5.81 | $8.63 | +50% | Bullish | |
| $4.24 | $5.90 | $8.88 | +53% | Bullish | |
| $5.67 | $8.30 | $13.18 | +115% | Bullish | |
| $10.25 | $16.35 | $28.05 | +324% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.86 | $3.86 | $4.50 | +0.00% |
| September 2026 | $3.20 | $3.76 | $4.54 | -2.46% |
| October 2026 | $3.25 | $3.85 | $4.68 | +2.23% |
| November 2026 | $3.23 | $3.84 | $4.70 | -0.32% |
| December 2026 | $3.19 | $3.80 | $4.69 | -0.89% |
Click any year to see its month-by-month BCYC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BCYC price prediction for 2026 points to an average of $3.86 (low $3.86, high $4.69) — a potential gain of 0% on today's $3.86. Price action looks broadly range-bound.
In 2027, BCYC is projected to trade between $3.17 and $5.06, averaging $3.91 — a potential gain of +1% from today's $3.86. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
Bicycle Therapeutics plc's 2028 outlook centres on $4.17, within a $3.31 to $5.56 range. That is up +7% on the projected 2027 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2029, BCYC could reach as high as $5.66, with a base case around $4.14 and support toward $3.23 — roughly +7% from $3.86. A consolidation phase looks the most probable path here.
Expect BCYC to range from $3.75 to $6.84 through 2030. The $4.90 average target implies a +27% move from current prices. That is up +18% on the projected 2029 average. Momentum favours further upside here.
The BCYC price prediction for 2031 points to an average of $5.62 (low $4.24, high $7.99) — a potential gain of +46% on today's $3.86. Buyers look set to stay in control over this stretch.
In 2032, BCYC is projected to trade between $4.09 and $7.93, averaging $5.49 — a potential gain of +42% from today's $3.86. That is -2% versus the projected 2031 average. Momentum favours further upside here.
Bicycle Therapeutics plc's 2033 outlook centres on $5.74, within a $4.22 to $8.41 range. That is up +4% on the projected 2032 average. That marks a +49% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BCYC could reach as high as $8.63, with a base case around $5.81 and support toward $4.22 — roughly +50% from $3.86. Momentum favours further upside here.
Expect BCYC to range from $4.24 to $8.88 through 2035. The $5.90 average target implies a +53% move from current prices. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BCYC price prediction for 2040 points to an average of $8.30 (low $5.67, high $13.18) — a potential gain of +115% on today's $3.86. Momentum favours further upside here.
In 2050, BCYC is projected to trade between $10.25 and $28.05, averaging $16.35 — a potential gain of +324% from today's $3.86. That is up +97% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCYC today (≈ 259.067358 BCYC) could be worth
$4,235.33
+$3,235.33 (+324%) by 2050 · US Dollar
Based on the average projected BCYC price of $16.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCYCwould be worth at today's price.
$1,000 invested in BCYC on Jul 31, 2025 (≈ 117.370886 BCYC) would be worth
$453.05
-$546.95 (-54.7%) today · 0.45× · US Dollar
Based on a BCYC entry price of $8.52 vs. today's $3.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.87 | $997.42 | -0.3% |
| 1 month ago | $4.21 | $916.86 | -8.3% |
| 3 months ago | $4.8 | $804.17 | -19.6% |
| 6 months ago | $6.49 | $594.76 | -40.5% |
| 1 year ago | $8.52 | $453.05 | -54.7% |
| All time (5.0y) ago | $29.65 | $130.19 | -87.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCYC forecast.
Our base-case forecast reaches $7.70 around 2040.
Implied market cap at $7.70: $387.87M
The multi-year outlook is bullish starting in 2030, with the 2030 average price at $4.98 and an ROI of 28.8%. The sentiment for 2030 is BULLISH, with continued bullish momentum into the following years.
The forecast shows further upside into 2031–2035, with 2031 average $5.66, 2032 average $5.55, 2033 average $5.81, 2034 average $5.86, and 2035 average $6.01, all labeled as BULLISH. These years project steady gains in average price and positive ROI trajectories.
By 2040, the average price is projected to be $8.37 with an ROI of 116.2%, and by 2050, the average price is projected to be $16.73 with an ROI of 332.4%, both labeled as BULLISH. The 2040 and 2050 figures imply substantial longer-term upside potential relative to the current level, though these are estimates and carry inherent uncertainty and no guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $4.98 in 2030, with a max of $6.79 and a min of $3.89, and an ROI of 28.8%. The sentiment is BULLISH.
Near term (2026–2029) is forecast Neutral with average prices around $3.87–$4.19. From 2030 onward the outlook is Bullish, with higher averages and ROIs through 2035, 2040, and 2050.
The forecast includes higher targets in the long term, with a 2040 max of $12.76 and a 2050 max of $27.36, indicating possible upside beyond $10 in the longer horizon.
Current price is $3.87 and market cap is $270.17M. It is ranked 3380.
The 30-day picture shows a BEARISH sentiment with RSI 50. The SMA50 is $4.28 and the SMA200 is $5.74, with support at $3.96 and resistance at $4.41. The 30-day range is $3.46–$4.32 and volatility is 30%.
Bicycle Therapeutics plc Community Discussion
0Share your Bicycle Therapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.